Skip to main content

Liver function test (SGPT) abnormality in 319 confirmed COVID-19 cases in Bangladesh



Deranged liver function abnormalities are well-recognized sequela of COVID-19 infection. Globally, there are studies dedicated to evaluate spectrum of liver injury by COVID-19. In this study, we have described the impact of COVID-19 on liver function tests in 319 confirmed COVID cases in Bangladesh. Our study aimed to determine the liver function alteration by COVID-19 in our population.


This study included all adult inpatients (> 18 years old) with laboratory-confirmed (RT-PCR) COVID-19 from March to April, 2020 in a tertiary COVID-dedicated hospital. We assessed liver function test and categorized patients according to COVID severity. This was a single-center, retrospective, observational study.


Among 319 patients with COVID-19, 36% had normal and 64% had abnormal liver function test. Out of this, 18% had 1–2 times, 42% had 2–3 times, and 19% had > 3 times upper limit of normal SGPT during admission. Fifty-seven (18%) patients presented with mild illness, 83 (26%) with moderate, 124 (39%) patients with severe, and 54 (17%) with critical COVID-19 during admission. Significant correlation was found between severity of COVID-19 and raised SGPT level.


More than half of patients presented during admission with abnormal liver function. COVID-19 has a significant impact on liver function derangement in this population.


Since 2019 COVID-19 has claimed millions of lives until now. On 11th March 2020, the World Health Organization (WHO) declared COVID-19 a pandemic [1]. It has only changed its name to Omicron in 2022 while the morbidity continued. The first COVID-19 case was detected in Bangladesh on March 8, 2020 [2]. Besides the involvement of the lungs, COVID-19 can involve the liver as well.

COVID-19 pathophysiology, disease progression, and optimal treatment are still under evaluation. Hepatic enzyme derangement is recognized as the most frequent extra-pulmonary manifestation of COVID-19 [3]. It is postulated that liver impairment may be due to the direct cytotoxic injury to hepatocyte by virus or indirectly by hypoxia, hepatotoxic drug, or severe inflammatory response [4]. Also, generalized inflammation and cytokine storm can cause multi-organ dysfunction including hepatic involvement [5, 6].

Recent studies suggest that more than half of patients with COVID-19 have liver injury [3, 7]. Elevated SGPT was reported ranging from 14 to 53% [8]. In Bangladesh, there are few studies to see the clinical profile of COVID cases [9, 10] and the relationship of COVID-19 hospital duration on liver enzymes [11]. The aim of this study was to see the spectrum of liver function tests and their relationship with the severity of COVID-19 patients in our population.


In this retrospective, single-center, observational study, we collected data from patients with COVID-19 who were admitted between March to April 2020. Demographic and clinical data were collected from hospital records onto a pre-defined spreadsheet. Diagnosis of COVID was based on clinical features (flu-like presentation, hypoxia, tachypnea, radiological findings) and RT-PCR test positive for COVID-19. COVID cases were clinically classified as mild, moderate, severe, and critical as defined in the Bangladesh national guideline on clinical management of COVID-19, version 8 [12].

Among the spectrum of liver function tests, we have picked SGPT only to assess liver injury to be focused. A patient was considered as having liver injury when alanine aminotransferase (ALT) or Serum glutamic pyruvic transaminase (SGPT) was more than 40 mU/ml.

Exclusion criteria

  1. 1.

    Patient with known chronic liver disease/preexisting liver disease

  2. 2.

    Patient taking alcohol

  3. 3.

    Patient on hepatotoxic drugs

  4. 4.



Sixty-three (63%) percent of the study population was male and the mean age was 43 years. Among 319 patients with COVID-19, 64% had abnormal liver function test. The presenting symptoms of the study population were fever (88%), cough (67%), sore throat (27%), severe weakness (31%), breathing difficulties (17%), gastrointestinal symptoms (14%), and anosmia (7%) (Fig. 1). Regarding comorbidities, 13% of the study population were diabetic and 16% were hypertensive. Other less common comorbidities are shown in the diagram (Fig. 2).

Fig. 1
figure 1

The clinical presentation of the study population with fever (88%), cough (67%), sore throat (27%), severe weakness (31%), and breathing difficulties (17%)

Fig. 2
figure 2

Comorbidities of the study population—13% were diabetic and 16% were hypertensive and 10% of patients had multiple comorbidities

Fifty-seven (18%) patients presented with mild illness, 83 (26%) with moderate, 124 (39%) patients with severe, and 54 (17%) with critical COVID-19 during admission (Fig. 3). Out of 64% raised LFT, 18% had 1–2 times, 42% had 2–3 times and 19% had > 3 times upper limit of normal SGPT during admission (Fig. 4). Significant correlation was found between severity of COVID-19 and raised SGPT level (Figs. 5 and 6). We set exclusion criteria as patient with known chronic liver disease/preexisting liver disease, patient taking alcohol, patient on hepatotoxic drugs, and pregnancy so that the preexisting contributing factors are of little significance.

Fig. 3
figure 3

Severity of COVID-19 of the study population showing the percentage of mild, moderate, severe, and critical COVID-19 cases

Fig. 4
figure 4

Spectrum of SGPT derangement in the study population. ULN-upper limit of normal SGPT

Fig. 5
figure 5

The correlation between severity of COVID 19 and SGPT. 1 = mild, 2 = moderate, 3 = severe and 4 = critical cases. SGPT was more raised in severe and critical group of patients

Fig. 6
figure 6

Receiver operating characteristic (ROC) curve to detect severity of disease by SGPT. The AUC (area under curve) is 0.83 which is statistically significant

Statistical analysis was carried out using Statistical Package for the Social Sciences (SPSS version 23.0 for Windows) and Microsoft Excel 2016. All quantitative data such as age, hemodynamic, and laboratory parameters were estimated using mean ± SD. Categorical data were analyzed as numbers and percentages. Qualitative variables were described as proportions. For normally distributed data, means were compared using independent t test. Mann–Whitney U test was applied for statistical analysis of skewed continuous variables and ordered categorical variables. χ2 test was used to compare categorical data. P values < 0.05 were considered statistically significant.


The present study was carried out on 319 COVID-19-positive patients admitted in a COVID-dedicated hospital. Several studies have described elevated liver panel in COVID-19 patients. Among them, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT) are reported to be raised [13, 14]. We have chosen SGPT only among the liver function panel to be more specific and precise.

There is increasing evidence of direct, virally mediated liver injury caused by COVID-19 leading to enzyme elevation. But the causes of raised liver enzyme are multi-dimensional. Sepsis, ischemia, drug-induced liver injury, and host immune response are also contributing [15]. Even long-term liver injury by COVID-19 is reported [16]. We have taken liver function test sample on admission so that the effect of other contributing factors (sepsis, hospital drug treatment-antiviral, antibiotics, biologics) are minimal.

In our study, we found that more than half of our patients had an increased value of liver enzymes. A cohort study on 1059 patients in New York found that 62% presented with at least 1 elevated liver enzyme [17]. A high prevalence of altered liver function test was noticed in Italian patients with COVID-19 [18]. We got similar findings in all these studies. Hao et al. [19] found that 28.2% of patients with COVID-19 presented with elevated liver enzyme levels on admission which was less compared to our study.

In this study, SGPT was more raised in severe patients than in mild COVID patients. In a systematic review study, liver function test elevations were more frequent in those with severe disease [20]. In a retrospective USA study of 2273 patients with COVID-19, 45% had mild liver injury, which was defined as levels of alanine aminotransferase (ALT) above the upper limit of normal (ULN) and below 2 times ULN. Liver injury was moderate (ALT between 2 and 5 times ULN) in 21% of cases and severe (above 5 times ULN) in 6.4% of cases. Patients with severe liver injury had a higher rate of intensive care unit admission [21]. Our study came out to be supportive of those studies. Eighteen percent of our study population had 1–2 times, 42% had 2–3 times and 19% had > 3 times the upper limit of normal SGPT during admission. Out of 54 patients in the critical group 31 had SGPT > 3 times ULN. SGPT was more raised in severe and critical group of patients which was statistically significant. Significant correlation was found between COVID-19 severity and SGPT elevation.

The limitation of the study is that being an observational, retrospective, and single-center study, may not reflect the whole population. Also, the follow-up of liver function tests during hospital stay was not included in the study that preclude the spectrum of liver injury related to COVID-19 treatment or sepsis.


The mechanism of liver injury by COVID-19 is multi-factorial. Further clinical studies are required for better insight into the mechanism of liver damage in severe to critical COVID-19 patients. This study highlighted the short-term effect of COVID on the liver. Also, more studies with long-term follow-up are needed to see long-term effect on the liver by COVID-19 in COVID long haulers.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.



Liver function test


Serum glutamic pyruvic transaminase


Alanine aminotransferase


Aspartate aminotransferase


Gamma-glutamyl transferase


Diabetes mellitus




Ischemic heart disease


Chronic kidney disease


  1. World Health Organization (2022) Coronavirus disease (covid-19) pandemic. Available from: Cited 2023 April 15

    Google Scholar 

  2. Islam MT, Talukder AK, Siddiqui MN, Islam T (2020) Tackling the COVID-19 pandemic: the Bangladesh perspective. J Public Health Res 9(4):1794

    Article  PubMed  PubMed Central  Google Scholar 

  3. Papadopoulos N, Vasileiadi S, Deutsch M (2020) Covid-19 and liver injury: where do we stand? Ann Gastroenterol 33:459–464

    PubMed  PubMed Central  Google Scholar 

  4. Sivandzadeh GRK, Askari H, Safarpour AR, Ejtehadi F, Raeis-Abdollahi E, Lari AV, Abazari MF, Tarkesh F, Lankarani KB (2021) COVID-19 infection and liver injury: clinical features, biomarkers, potential mechanisms, treatment, and management challenges. World J Clin Cases 9(22):6178–6200

    Article  PubMed  PubMed Central  Google Scholar 

  5. Mustafa MI, Abdelmoneim AH, Mahmoud EM, Makhawi AM (2020) Cytokine storm in COVID-19 patients, its impact on organs and potential treatment by QTY code-designed detergent-free chemokine receptors. Mediators Inflamm 2020:1–7

    Article  Google Scholar 

  6. Ali FE, Mohammedsaleh ZM, Ali MM, Ghogar OM (2021) Impact of cytokine storm and systemic inflammation on liver impairment patients infected by SARS-CoV-2: prospective therapeutic challenges. World J Gastroenterol 27(15):1531–1552

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C, Zhang Y, Huang S, Liu Z, Cheng J (2020) Clinical features of COVID-19-related liver functional abnormality. Clin Gastroenterol Hepatol 18(7):1561–1566

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, Li Z, Zhou G, Gou J, Qu J, Sun Y (2020) COVID-19: abnormal liver function tests. J Hepatol 73(3):566–574

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Al Mamun SA, Noor M, Jahan R, Khan S (2021) Demographic and clinical profile of COVID-19 patients in a tertiary care private hospital of Dhaka, Bangladesh: an observational study. Bangladesh J Med 32(1):25–30

    Article  Google Scholar 

  10. Shaha M, Islam MA, Huq F, Roy B, Kabir MA, Salimullah M, Al Mahtab M, Akbar SM (2021) Clinical manifestations of hospitalized COVID-19 patients in Bangladesh: a 14-day observational study. Euroasian J Hepatogastroenterol 11(1):14–20

    PubMed  PubMed Central  Google Scholar 

  11. Sarker SS, Hasan SA, Islam MS, Das N, Rahman KM, Alam MR, Kabir MA (2021) Length of hospital stay of COVID-19 patients and its relationship with liver function abnormalities. Bangabandhu Sheikh Mujib Med Univ J 14(3):8–12

    Article  Google Scholar 

  12. Ministry of Health & Family Welfare Government of the People’s Republic of Bangladesh (2020) National guidelines on clinical management of COVID-19, 8th edn. Directorate General of Health Services, Dhaka

    Google Scholar 

  13. Bertolini A, van de Peppel IP, Bodewes FAJA, Moshage H, Fantin A, Farinati F, Fiorotto R, Jonker JW, Strazzabosco M, Verkade HJ, Peserico G (2020) Abnormal liver function tests in patients with COVID-19: relevance and potential pathogenesis. Hepatology 72(5):1864–1872

    Article  CAS  PubMed  Google Scholar 

  14. Altaf A, Abbas Z, Mandviwalla HA, Qadeer MA, Siyal M, Tariq M, Ghafoor A, Karamat M, Shahid B, Ali M (2021) Severe COVID-19 associated with liver injury in patients without preexisting liver disease. Cureus 13(4):e14705

    PubMed  PubMed Central  Google Scholar 

  15. Nardo AD, Schneeweiss-Gleixner M, Bakail M, Dixon ED, Lax SF, Trauner M (2021) Pathophysiological mechanisms of liver injury in COVID-19. Liver Int 41(1):20–32

    Article  CAS  PubMed  Google Scholar 

  16. Heidari F (2022) Radiological society of North America, lasting liver injury following COVID-19 infection measured by ultrasound shear wave elastography.

    Google Scholar 

  17. Hajifathalian K, Krisko T, Mehta A, Kumar S, Schwartz R, Fortune B, Sharaiha RZ, WCM-GI research group (2020) Gastrointestinal and hepatic manifestations of 2019 novel coronavirus disease in a large cohort of infected patients from New York: clinical implications. Gastroenterology 159(3):1137–1140

    Article  CAS  PubMed  Google Scholar 

  18. Lenti MV, Borrelli de Andreis F, Pellegrino I, Klersy C, Merli S, Miceli E, Aronico N, Mengoli C, Di Stefano M, Cococcia S, Santacroce G, Soriano S, Melazzini F, Delliponti M, Baldanti F, Triarico A, Corazza GR, Pinzani M, Di Sabatino A, Internal Medicine Covid-19 Team (2020) Impact of COVID-19 on liver function: results from an internal medicine unit in Northern Italy. Intern Emerg Med 15(8):1399–1407

    Article  PubMed  PubMed Central  Google Scholar 

  19. Hao SR, Zhang SY, Lian JS, Jin X, Ye CY, Cai H, Zhang XL, Hu JH, Zheng L, Zhang YM, Jia HY, Yu GD, Wang XY, Gu JQ, Lu YF, Yu XP, Yu L, Xiang DR, Ye CY, Jin CL, Qiu YQ, Li LJ, Sheng JF, Liang TB, Yang YD (2020) Liver enzyme elevation in coronavirus disease 2019: a multicenter, retrospective, cross-sectional study. Am J Gastroenterol 115(7):1075–1083

    Article  PubMed  Google Scholar 

  20. Kumar-M P, Mishra S, Jha DK, Shukla J, Choudhury A, Mohindra R, Mandavdhare HS, Dutta U, Sharma V (2020) Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis. Hepatol Int 14(5):711–722

    Article  PubMed  Google Scholar 

  21. Phipps MM, Barraza LH, LaSota ED, Sobieszczyk ME, Pereira MR, Zheng EX, Fox AN, Zucker J, Verna EC (2020) Acute liver injury in COVID-19: prevalence and association with clinical outcomes in a large US cohort. Hepatology 72(3):807–817

    Article  CAS  PubMed  Google Scholar 

Download references


The author is thankful to Abdus Salam, Professor of Dhaka University, Bangladesh and Al-Amin Fahim, graduate students of the University of Dhaka for help with statistics.



Author information

Authors and Affiliations



MY contributed to the research concept, manuscript writing, and data analysis while NKB did data collection, correction and AA contributed to the revision of the article. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Mahbuba Yesmin.

Ethics declarations

Ethics approval and consent to participate

The study was performed as a clinical audit using collected routine clinical data and is exempt from the need to take specified informed written consent from the patients. The study was approved by the local ethics committee of the hospital.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yesmin, M., Biswas, N.K. & Alam, A. Liver function test (SGPT) abnormality in 319 confirmed COVID-19 cases in Bangladesh. Egypt Liver Journal 13, 48 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: